AU Patent

AU2022324615A1 — Cannabinoid derivatives and their use

Assigned to Demeetra Agbio Inc · Expires 2024-02-15 · 2y expired

What this patent protects

Provided herein are methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, for example, in the treatment of a mental health disorder or chronic inflammatory disease.

USPTO Abstract

Provided herein are methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, for example, in the treatment of a mental health disorder or chronic inflammatory disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022324615A1
Jurisdiction
AU
Classification
—
Expires
2024-02-15
Drug substance claim
No
Drug product claim
No
Assignee
Demeetra Agbio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.